Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Interest Expenses (2022 - 2025)

Historic Interest Expenses for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $1708.0.

  • 60 Degrees Pharmaceuticals' Interest Expenses rose 1642.81% to $1708.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6141.0, marking a year-over-year decrease of 4855.06%. This contributed to the annual value of $7912.0 for FY2024, which is 9965.4% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Interest Expenses stood at $1708.0, which was up 1642.81% from $1221.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Interest Expenses registered a high of $1.2 million during Q3 2022, and its lowest value of $1221.0 during Q2 2025.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Interest Expenses had a median value of $4533.5 in 2023 and averaged $394743.6.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Interest Expenses crashed by 9987.72% in 2024 and then skyrocketed by 2767.48% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Interest Expenses stood at $1.1 million in 2022, then crashed by 99.51% to $5446.0 in 2023, then plummeted by 73.89% to $1422.0 in 2024, then grew by 20.11% to $1708.0 in 2025.
  • Its last three reported values are $1708.0 in Q3 2025, $1221.0 for Q2 2025, and $1790.0 during Q1 2025.